Updates from the 2025 American Society of Hematology Annual Meeting

The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 276 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific Advisory Board (SAB) and grantees, contributing to an abstract presented at the conference.

Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provides a critical forum for leading hematologists/oncologists to present their findings to over 20,000 of their peers.

Among the distinguished scientists attending, more than 80 Foundation-affiliated scientists presented at the 2025 ASH Annual Meeting. In addition to the Foundation’s representation through presentations, the Foundation’s researchers contributed to 674 lymphoma-related abstracts.

Highlights from ASH 2025:

• Phase II Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma: 15-year Follow-Up Data from MDACC Trial
• Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A Newly Identified Role for IL-5 in Regulating CAR T-associated Toxicity and Efficacy
• Sasp-Driven Immune Evasion Defines a Novel African Ancestry-Associated DLBCL Subtype with Distinctive Molecular and Immune Vulnerabilities
• Real-World Treatment Patterns, Patient Characteristics, and Outcomes of CBTKI-Based Therapies Amongst a Contemporary Cohort of Patients with R/R MCL in the United States
• Association Between Adolescent and Young Adult (AYA) Age, Acuity of Illness at Diagnosis, and Clinical Trial Enrollment Among Patients with Hematologic Malignancies at a Pediatric Center